Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of CB-708, an orally administered small molecule inhibitor of CD73

Trial Profile

A clinical study of CB-708, an orally administered small molecule inhibitor of CD73

Planning
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs CB 708 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jan 2019 According to a Calithera Biosciences media release, the company expects acceptance of IND application and initiation of the study in 2H 2019.
    • 20 Aug 2018 New trial record
    • 07 Aug 2018 According to a Calithera Biosciences media release, the company is expected to file an IND for CB-708 and to start this study in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top